

Vlidaplit M Forte Tablet

Composition:

Each film-coated bilayered tablet contains:

Vildagliptin I.P. 50 mg

Metformin Hydrochloride I.P. 1000 mg (as sustained release)

Excipients q.s.

Description:

Vlidaplit M Forte Tablet is a combination of Vildagliptin, a DPP-4 inhibitor, and Metformin, a biguanide class antidiabetic agent. This combination is used for the management of type 2 diabetes mellitus in adults, especially when diet, exercise, and monotherapy with either drug do not provide adequate glycemic control.

Indications:

- Type 2 Diabetes Mellitus
- For patients inadequately controlled on Metformin monotherapy
- As part of a combination therapy with other antidiabetic agents

Mechanism of Action:

Vildagliptin increases the levels of incretin hormones (GLP-1 and GIP), thereby enhancing glucose-dependent insulin secretion and suppressing glucagon release.

Metformin works by decreasing hepatic glucose production, improving insulin sensitivity, and enhancing peripheral glucose uptake.

Dosage and Administration:

Dose to be individualized based on clinical response and tolerability.

Usual adult dose: One tablet once or twice daily with meals.

Tablet to be swallowed whole with water; do not crush or chew.

Side Effects:

Nausea

Diarrhea

Abdominal pain

Headache

Dizziness

Hypoglycemia (especially when used with other antidiabetics)

Rare: Lactic acidosis (Metformin-related)

Precautions:

Assess renal function before initiating and periodically thereafter

Discontinue in cases of dehydration, surgery, or radiologic studies involving contrast

Not recommended in patients with hepatic impairment

Monitor liver enzymes during therapy

Use with caution in elderly and in patients with heart failure

Storage:

Store in a cool, dry place below 25°C. Protect from light and moisture. Keep out of reach of children.

Manufactured in India for:



Cafoli Lifecare Pvt. Ltd.

(An ISO 9001: 2015 Certified Co.)

Plot no.: 367-FF, Industrial Area Phase-I,

Panchkula-134113

TM: Trademark Applied for